Literature DB >> 28797359

Primary Prevention of Cardiovascular Disease in Diabetes Mellitus.

Jonathan D Newman1, Arthur Z Schwartzbard2, Howard S Weintraub2, Ira J Goldberg3, Jeffrey S Berger2.   

Abstract

Type 2 diabetes mellitus (T2D) is a major risk factor for cardiovascular disease (CVD), the most common cause of death in T2D. Yet, <50% of U.S. adults with T2D meet recommended guidelines for CVD prevention. The burden of T2D is increasing: by 2050, approximately 1 in 3 U.S. individuals may have T2D, and patients with T2D will comprise an increasingly large proportion of the CVD population. The authors believe it is imperative that we expand the use of therapies proven to reduce CVD risk in patients with T2D. The authors summarize evidence and guidelines for lifestyle (exercise, nutrition, and weight management) and CVD risk factor (blood pressure, cholesterol and blood lipids, glycemic control, and the use of aspirin) management for the prevention of CVD among patients with T2D. The authors believe appropriate lifestyle and CVD risk factor management has the potential to significantly reduce the burden of CVD among patients with T2D.
Copyright © 2017 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cardiovascular disease; primary prevention; type 2 diabetes

Mesh:

Year:  2017        PMID: 28797359      PMCID: PMC5656394          DOI: 10.1016/j.jacc.2017.07.001

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  71 in total

1.  Redefining Blood-Pressure Targets--SPRINT Starts the Marathon.

Authors:  Vlado Perkovic; Anthony Rodgers
Journal:  N Engl J Med       Date:  2015-11-09       Impact factor: 91.245

2.  Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

Authors:  Steven P Marso; Stephen C Bain; Agostino Consoli; Freddy G Eliaschewitz; Esteban Jódar; Lawrence A Leiter; Ildiko Lingvay; Julio Rosenstock; Jochen Seufert; Mark L Warren; Vincent Woo; Oluf Hansen; Anders G Holst; Jonas Pettersson; Tina Vilsbøll
Journal:  N Engl J Med       Date:  2016-09-15       Impact factor: 91.245

3.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

Authors: 
Journal:  Lancet       Date:  2000-01-22       Impact factor: 79.321

4.  Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Lars H Lindholm; Hans Ibsen; Björn Dahlöf; Richard B Devereux; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Stevo Julius; Sverre E Kjeldsen; Krister Kristiansson; Ole Lederballe-Pedersen; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Peter Aurup; Jonathan Edelman; Steven Snapinn
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

5.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

Authors:  D M Nathan; S Genuth; J Lachin; P Cleary; O Crofford; M Davis; L Rand; C Siebert
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245

6.  Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.

Authors:  Peter Gaede; Pernille Vedel; Nicolai Larsen; Gunnar V H Jensen; Hans-Henrik Parving; Oluf Pedersen
Journal:  N Engl J Med       Date:  2003-01-30       Impact factor: 91.245

7.  Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005).

Authors:  David M Nathan; Bernard Zinman; Patricia A Cleary; Jye-Yu C Backlund; Saul Genuth; Rachel Miller; Trevor J Orchard
Journal:  Arch Intern Med       Date:  2009-07-27

8.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

9.  Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators.

Authors: 
Journal:  JAMA       Date:  1992-09-09       Impact factor: 56.272

Review 10.  Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association.

Authors:  Sarah D de Ferranti; Ian H de Boer; Vivian Fonseca; Caroline S Fox; Sherita Hill Golden; Carl J Lavie; Sheela N Magge; Nikolaus Marx; Darren K McGuire; Trevor J Orchard; Bernard Zinman; Robert H Eckel
Journal:  Diabetes Care       Date:  2014-08-11       Impact factor: 19.112

View more
  41 in total

Review 1.  Cardiometabolic-Based Chronic Disease, Addressing Knowledge and Clinical Practice Gaps: JACC State-of-the-Art Review.

Authors:  Jeffrey I Mechanick; Michael E Farkouh; Jonathan D Newman; W Timothy Garvey
Journal:  J Am Coll Cardiol       Date:  2020-02-11       Impact factor: 24.094

Review 2.  Weighing the Anti-Ischemic Benefits and Bleeding Risks from Aspirin Therapy: a Rational Approach.

Authors:  Sagar Dugani; Jeffrey M Ames; JoAnn E Manson; Samia Mora
Journal:  Curr Atheroscler Rep       Date:  2018-02-21       Impact factor: 5.113

Review 3.  Towards more specific treatment for diabetic dyslipidemia.

Authors:  Valentina Rodriguez; Jonathan D Newman; Arthur Z Schwartzbard
Journal:  Curr Opin Lipidol       Date:  2018-08       Impact factor: 4.776

4.  Predictive Value of Non-high-Density Lipoprotein Cholesterol and Neutrophil-Lymphocyte Ratio for Coronary Artery Vulnerable Plaques in Type 2 Diabetes Mellitus.

Authors:  Xiyi Huang; Shaomin Yang; Qiang Zhao; Xinjie Chen; Jialing Pan; Shaofen Lai; Fusheng Ouyang; Lingda Deng; Yongxing Du; Xiaohong Li; Qiugen Hu; Baoliang Guo; Jiemei Liu
Journal:  Front Cardiovasc Med       Date:  2022-06-20

Review 5.  The Effects of Physical Exercise on Fatty Liver Disease.

Authors:  Dirk J van der Windt; Vikas Sud; Hongji Zhang; Allan Tsung; Hai Huang
Journal:  Gene Expr       Date:  2017-12-06

Review 6.  The Changing Landscape of Diabetes Therapy for Cardiovascular Risk Reduction: JACC State-of-the-Art Review.

Authors:  Jonathan D Newman; Anish K Vani; Jose O Aleman; Howard S Weintraub; Jeffrey S Berger; Arthur Z Schwartzbard
Journal:  J Am Coll Cardiol       Date:  2018-10-09       Impact factor: 24.094

Review 7.  A network analysis framework of genetic and nongenetic risks for type 2 diabetes.

Authors:  Yuan Zhang; Shu Li; Zhi Cao; Yangyang Cheng; Chenjie Xu; Hongxi Yang; Li Sun; Hongxiao Jiao; Ju Wang; Wei-Dong Li; Yaogang Wang
Journal:  Rev Endocr Metab Disord       Date:  2020-09-14       Impact factor: 6.514

Review 8.  Epidemiology and Economic Burden of Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus in Spain: A Systematic Review.

Authors:  Esther Artime; Irene Romera; Silvia Díaz-Cerezo; Elías Delgado
Journal:  Diabetes Ther       Date:  2021-05-03       Impact factor: 2.945

9.  Melatonin Attenuates Diabetic Myocardial Microvascular Injury through Activating the AMPK/SIRT1 Signaling Pathway.

Authors:  Bin Wang; Jinyu Li; Mi Bao; Runji Chen; Haiyan Li; Binger Lu; Meixin Chen; Danmei Huang; Yanmei Zhang; Fenfei Gao; Ganggang Shi
Journal:  Oxid Med Cell Longev       Date:  2021-05-27       Impact factor: 6.543

Review 10.  Blood Sugar Regulation for Cardiovascular Health Promotion and Disease Prevention: JACC Health Promotion Series.

Authors:  Peter E H Schwarz; Patrick Timpel; Lorenz Harst; Colin J Greaves; Mohammed K Ali; Jeffrey Lambert; Mary Beth Weber; Mohamad M Almedawar; Henning Morawietz
Journal:  J Am Coll Cardiol       Date:  2018-10-09       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.